Anticoagulant and endothelial-promoting bionic artificial blood vessel and preparation method thereof
By applying polyphenol-metal-polypeptide copolymer coating on artificial blood vessels, the problems of thrombosis and restenosis of small-sized artificial blood vessels after long-term implantation are solved, and stable nitric oxide release and tissue cell remodeling are achieved, which improves the Pathogenesis and biocompatibility reduce production costs.
Patent Information
- Application Number
- CN202411170348.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-26
AI Technical Summary
Existing small-sized artificial blood vessels are prone to thrombosis, restenosis and difficulty in remodeling of tissue cells after long-term implantation, resulting in low patency rates and short half-life of exogenous nitric oxide-releasing drugs and high risk.
Anticoagulation and endothelial bionic artificial blood vessels are prepared by electrospinning and other technologies, using porous polymer substrates and polyphenol-metal-polypeptide copolymer coatings, and the release of nitric oxide is catalyzed through polyphenols and metal ions, and the release of nitric oxide through polypeptides Covalent bonding improves the stability of the coating and anti-blood flow erosion ability.
It achieves stable and continuous nitric oxide release, reduces the risk of thrombosis and restenosis, improves the remodeling and endothelial function of tissue cells, enhances the patency and biocompatibility of artificial blood vessels, and reduces production costs.
Smart Images

Figure CN118662699B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of bionic materials, in particular to an anti-coagulation and endothelial-promoting bionic artificial blood vessel and a preparation method thereof. Background Art
[0002] At present, with the aging of society and the change of people's lifestyle, the harm of cardiovascular-related diseases is particularly prominent. Based on this, medical biomaterials such as vascular stents and artificial blood vessels have improved the effect of medical treatment. However, medical biomaterials have exposed some problems that cannot be ignored in clinical applications, such as the probability of late thrombosis and restenosis of vascular stents after implantation, and infection during the use of central venous catheters. Therefore, it is imperative to improve cardiovascular medical materials.
[0003] Blood-contact materials that exist in the human body for a long time are often cardiovascular stents and artificial blood vessels. Promoting endothelialization on the surface of materials is an effective way to solve the thrombosis, inflammation, and restenosis caused by device implantation. Here, we will take artificial blood vessels as an example to explain in detail.
[0004] Artificial blood vessels based on porous polymer materials have a physical structure similar to that of the extracellular matrix, sufficient mechanical properties that match vascular tissue, and high porosity, which makes them a possible choice for the preparation of artificial blood vessels. However, existing porous polymer artificial blood vessels lack physiological activity and good tissue compatibility, cannot secrete physiological factors produced by autologous blood vessels, and are difficult for tissue cells to regenerate and remodel, which may lead to a series of problems such as chronic foreign body reactions, thrombosis, and intimal hyperplasia, making small-sized artificial blood vessels less effective in long-term implantation therapy. Nitric oxide is an important signaling molecule produced in blood vessels in the body. Nitric oxide controls vasodilation, inhibits platelet aggregation and its adhesion to the blood vessel wall, and reduces the risk of intimal hyperplasia. In view of the significant therapeutic effect of nitric oxide, exogenous nitric oxide-releasing drugs are used in artificial blood vessels. However, the inherent short half-life of the drug and the risks that may be caused by systemic absorption cannot be ignored. Summary of the invention
[0005] Technical problems solved by the present invention:
[0006] How to maintain stable and continuous release of nitric oxide from artificial blood vessels, reduce the risk of thrombosis and restenosis, improve the patency rate of small-sized artificial blood vessels, accelerate tissue cell remodeling and restore its tissue structure and physiological function.
[0007] The technical solution adopted by the present invention is:
[0008] In view of the above technical problems, the purpose of the present invention is to provide an anti-coagulation and endothelial-promoting bionic artificial blood vessel, a preparation method thereof, and its application. The specific contents are as follows:
[0009] First, the present invention provides an anti-coagulation and endothelial-promoting bionic artificial blood vessel, comprising:
[0010] A porous polymer substrate and a coating bonded to the porous polymer substrate; the porous polymer substrate is doped with metal ions I;
[0011] The coating is a polyphenol-metal-polypeptide copolymer.
[0012] According to some embodiments, the raw material of the porous polymer substrate includes at least one of polylactic acid, polycaprolactone, polyglycolic acid, polycarbonate, polyurethane, polydioxanone, polyamide, polyether polyol, and polyethylene terephthalate.
[0013] According to some embodiments, the forming method of the porous polymer substrate includes at least one of electrospinning, electrostatic direct writing, template method, freeze drying, 3D printing, solution spinning, melt spinning, foaming, weaving, and melt blowing.
[0014] According to some embodiments, the polyphenol-metal-polypeptide copolymer comprises:
[0015] The polyphenols include at least one of dopamine (DA), gallic acid (GA) and its derivatives, tannic acid (TA), pyrogallic acid (PG), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC), epigallocatechin gallate (EGCG), levodopa, and dextrodopa.
[0016] The metal is a metal ion II that can catalyze the release of nitric oxide from an endogenous nitric oxide donor, and the metal ion II includes at least one of a copper ion, an iron ion, a zinc ion, a nickel ion, a cobalt ion, and a manganese ion;
[0017] The polypeptide has at least one group bonding to polyphenol-metal and at least one functional polypeptide sequence.
[0018] Further, the group includes at least one of carboxyl, hydroxyl, amino, hydrazide, mercapto, and isocyanate; further, the group includes at least one of mercapto, amino, and hydrazide.
[0019] Furthermore, the functional polypeptide sequence includes at least one polypeptide sequence having anti-coagulation, endothelial-promoting, anti-inflammatory, anti-platelet, and smooth muscle hyperplasia inhibition functions.
[0020] According to some embodiments, the porous polymer substrate is doped with metal ions I;
[0021] The metal ion I includes at least one of copper ion, iron ion, zinc ion, nickel ion, cobalt ion and manganese ion;
[0022] The mass ratio of metal ion I to porous polymer substrate is 1:30~60.
[0023] Second, the present invention provides a method for preparing the anticoagulant and endothelial-promoting bionic artificial blood vessel as mentioned above, comprising the following steps:
[0024] S1 The porous polymer substrate is subjected to a hydrophilic treatment to obtain a first treated body;
[0025] S2 placing the first treated body in a treatment solution containing polyphenol-metal ions to obtain a second treated body;
[0026] S3 placing the second treated body in a treatment solution containing the polypeptide to obtain an anti-coagulation and endothelial-promoting bionic artificial blood vessel.
[0027] According to some embodiments, the hydrophilization treatment includes at least one of plasma treatment, acid treatment, alkali treatment, chromium pickling solution treatment, cleaning treatment, sodium naphthalene treatment, and irradiation treatment.
[0028] According to some embodiments, in S2, the mass concentration of the treatment solution containing polyphenol-metal ions is 1 to 30%.
[0029] According to some embodiments, in S3, the mass concentration of the treatment solution containing the polypeptide is 0.5-50%.
[0030] The technical mechanism and beneficial effects adopted by the present invention are as follows:
[0031] (1) The anticoagulant and pro-endothelial bionic artificial blood vessels provided by the present invention organically combine polyphenols, metal ions that can catalyze the release of nitric oxide, and polypeptides, thereby giving the artificial blood vessels the functions of anticoagulation, promoting endothelialization, inhibiting inflammatory response, and regulating smooth muscle growth, thereby solving the problems of difficult endothelialization of small-sized artificial blood vessels and high risk of restenosis in the prior art.
[0032] (2) The anticoagulant and pro-endothelial bionic artificial blood vessel provided by the present invention has an anticoagulant and pro-endothelial coating that catalyzes the release of nitric oxide from endogenous nitric oxide donors. The concentration of dopamine and copper chloride in the aqueous solution can be effectively adjusted to maintain nitric oxide at an appropriate physiological concentration level.
[0033] (3) The anticoagulant and pro-endothelial bionic artificial blood vessel provided by the present invention has a polyphenol-metal coating with good reactivity, and it is easy to further introduce polypeptides with different functions on its surface, thereby giving the artificial blood vessel multiple biological properties, thereby meeting the requirements of patients with different lesions for artificial blood vessel performance.
[0034] (4) The anticoagulant and endothelial-promoting bionic artificial blood vessels provided by the present invention introduce the polypeptide to the surface of the polyphenol coating through efficient chemical reactions between the thiol, amino, hydrazide and other groups on the polypeptide and the polyphenol-metal coating. The operation process only requires soaking the polyphenol-metal coating material in the polypeptide aqueous solution. This method is efficient and clean, and will not cause adverse effects on the polypeptide solution. Therefore, the expensive polypeptide solution can be reused many times, thereby reducing production costs. In the prior art, the polypeptide is grafted onto the coating surface through self-assembly, which is a non-covalent effect and is easily lost under the scouring effect of blood flow. Therefore, we use the polypeptide to combine with the polyphenol-metal coating through covalent bonds, which can effectively resist blood flow scouring and exert long-term and stable biological functions.
[0035] (5) The anticoagulant and endothelial-promoting bionic artificial blood vessel provided by the present invention adds metal ions that can interact with polyphenols to the porous polymer substrate, thereby enhancing the adhesion between the polyphenol-metal coating and the substrate, thereby improving the stability and durability of the coating.
[0036] (6) The anticoagulant and endothelial-promoting bionic artificial blood vessel provided by the present invention utilizes a cheap and safe processing technology to attach a dense polyphenol-metal-polypeptide coating on the surface of the substrate, thereby endowing the substrate with good anticoagulant and endothelial-promoting properties. The technology used in the method is safe, economical, and conducive to large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 This is a physical picture of the artificial blood vessel PCL / Cu prepared in Example 1;
[0038] Figure 2 This is a physical picture of the artificial blood vessel PCL / Cu-PDA / Cu-REDV prepared in Example 5;
[0039] Figure 3 The results of the tape test coating removal rate of the artificial blood vessel PCL / Cu-PDA / Cu-2 prepared in Example 3 and the artificial blood vessel PCL-PDA / Cu prepared in Example 4 are shown;
[0040] Figure 4 The result graphs are of the rate of nitric oxide release from nitric oxide donors catalyzed by the artificial blood vessels PCL prepared in Example 2, and the artificial blood vessels PCL / Cu-PDA / Cu-1, PCL / Cu-PDA / Cu-2, PCL / Cu-PDA / Cu-3, and PCL / Cu-PDA / Cu-4 prepared in Example 3;
[0041] Figure 5The water contact angle results of the artificial blood vessel PCL / Cu-PDA / Cu-2 prepared in Example 3 and the artificial blood vessel PCL-PDA / Cu prepared in Example 4 after being immersed in PBS for different time periods;
[0042] Figure 6 The result graphs are of the rate of catalyzing the release of nitric oxide by the nitric oxide donor after the artificial blood vessel PCL / Cu-PDA / Cu-2 prepared in Example 3 and the artificial blood vessel PCL-PDA / Cu prepared in Example 4 were immersed in PBS for different time periods;
[0043] Figure 7 This is a scanning electron microscopic image of platelet adhesion of the artificial blood vessel PCL prepared in Example 2;
[0044] Figure 8 This is a scanning electron microscopic image of platelet adhesion to the artificial blood vessel PCL / Cu-PDA / Cu-REDV containing the polyphenol-metal-peptide coating prepared in Example 5;
[0045] Fig. 9 These are the endothelial cell adhesion results of the artificial blood vessel PCL prepared in Example 2, the polyphenol-metal coated artificial blood vessel PCL / Cu-PDA / Cu-2 prepared in Example 3, and the polyphenol-metal-polypeptide coated artificial blood vessel PCL / Cu-PDA / Cu-REDV in Example 5. DETAILED DESCRIPTION
[0046] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0047] Example 1 - Preparation of artificial blood vessel substrate (PCL / Cu): comprising the following steps,
[0048] (1) dissolving polycaprolactone and copper chloride together in N,N-dimethylformamide to prepare a spinning solution with a polycaprolactone mass fraction of 20% and a copper chloride mass fraction of 0.5%;
[0049] (2) Add the spinning solution into the electrospinning machine capacity tube for electrospinning. The spinning voltage is 18 kV, the receiving distance is 15 cm, the spinning solution propulsion speed is 1 mL / h, the receiving device is a steel tube with an outer diameter of 2 mm, the rotation speed is 300 rpm, and the spinning width is 10 cm.
[0050] (3) After the electrospinning is completed, the obtained spinning membrane is removed from the receiving device and placed in a vacuum drying oven for drying to obtain the artificial blood vessel substrate PCL / Cu.
[0051] Example 2-Preparation of artificial blood vessel substrate (PCL): comprising the following steps,
[0052] (1) dissolving polycaprolactone in N,N-dimethylformamide to prepare a polymer spinning solution with a mass fraction of 20%;
[0053] (2) Add the polycaprolactone spinning solution into the electrospinning machine capacity tube for electrospinning. The spinning voltage is 18 kV, the receiving distance is 15 cm, the spinning solution propulsion speed is 1 mL / h, the receiving device is a steel tube with an outer diameter of ~2 mm, the rotation speed is 300 rpm, and the spinning width is 10 cm;
[0054] (3) After the electrospinning is completed, the obtained spinning membrane is removed from the receiving device and placed in a vacuum drying oven for drying to obtain the artificial blood vessel substrate PCL.
[0055] Example 3-Polyphenol-metal coating treatment on the surface of artificial blood vessels (PCL / Cu-PDA / Cu): comprising the following steps:
[0056] (1) The artificial blood vessel obtained in Example 1 was treated with PCL / Cu plasma for 2 min;
[0057] (2) The artificial blood vessels after plasma treatment were immersed in an aqueous solution containing dopamine / copper chloride and shaken for 24 hours. The pH of the aqueous solution was 8.5, the dopamine concentration was 0.10 mg / mL, and the copper chloride concentration was adjusted to 0.01 mg / mL, 0.05 mg / mL, 0.1 mg / mL, and 0.15 mg / mL to prepare a series of metal-polyphenol coated artificial blood vessels with different copper ion contents, namely PCL / Cu-PDA / Cu-1, PCL / Cu-PDA / Cu-2, PCL / Cu-PDA / Cu-3, and PCL / Cu-PDA / Cu-4.
[0058] Example 4-Polyphenol-metal coating treatment on the surface of artificial blood vessels (PCL-PDA / Cu): comprising the following steps:
[0059] (1) The artificial blood vessel obtained in Example 2 was treated with PCL plasma for 2 min;
[0060] (2) The artificial blood vessel after plasma treatment was immersed in an aqueous solution containing dopamine / copper chloride and shaken for 24 hours, wherein the pH of the aqueous solution was 8.5, the dopamine concentration was 0.10 mg / mL, and the copper chloride concentration was adjusted to 0.05 mg / mL to obtain PCL-PDA / Cu.
[0061] Example 5-Introduction of polypeptide treatment on the surface of artificial blood vessels containing polyphenol-metal coating (PCL / Cu-PDA / Cu-REDV): comprising the following steps,
[0062] (1) The polyphenol-metal coated artificial blood vessel PCL / Cu-PDA / Cu-2 obtained in Example 3 was immersed in an aqueous solution of REDV polypeptide containing a thiol functional group (SH-REDV, i.e. SH-arginine-glutamic acid-aspartic acid-valine, Hangzhou Zhuan Peptide Biotechnology Co., Ltd.) for 2 h, and the concentration of SH-REDV was 0.10 mg / mL;
[0063] (2) Drying the soaked artificial blood vessel in a nitrogen atmosphere to obtain an artificial blood vessel PCL / Cu-PDA / Cu-REDV with a polyphenol-metal-polypeptide coating.
[0064] Example 6-Introduction of polypeptide treatment on the surface of artificial blood vessels containing polyphenol-metal coating (PCL / Cu-PDA / Cu-BVLD): comprising the following steps,
[0065] (1) The artificial blood vessel was further modified by using the polypeptide BVLD having anticoagulant function. The polyphenol-metal coated artificial blood vessel PCL / Cu-PDA / Cu-2 obtained in Example 3 was immersed in an aqueous solution of a BVLD polypeptide containing an amino functional group (NH2-BVLD, i.e., NH2-bivalirudin polypeptide, Hangzhou Peptide Biotechnology Co., Ltd.) for 4 h, and the concentration of NH2-BVLD was 0.15 mg / mL;
[0066] (2) Drying the soaked artificial blood vessel in a nitrogen atmosphere to obtain an artificial blood vessel PCL / Cu-PDA / Cu-BVLD with a polyphenol-metal-polypeptide coating.
[0067] Example 7-Introduction of polypeptide treatment on the surface of artificial blood vessels containing polyphenol-metal coating (PCL / Cu-PDA / Cu-AMP): comprising the following steps,
[0068] (1) The artificial blood vessel was further modified by selecting a polypeptide AMP with antibacterial function. The polyphenol-metal coated artificial blood vessel PCL / Cu-PDA / Cu-2 obtained in Example 3 was immersed in an aqueous solution of AMP polypeptide containing a thiol functional group (SH-AMP, AMP is an antibacterial peptide, Hangzhou Zhuan Peptide Biotechnology Co., Ltd.) for 4 h, and the concentration of SH-AMP was 0.2 mg / mL;
[0069] (2) Drying the soaked artificial blood vessel in a nitrogen atmosphere to obtain an artificial blood vessel PCL / Cu-PDA / Cu-AMP with a polyphenol-metal-peptide coating.
[0070] Example 8-Preparation of artificial blood vessel substrate (PLCL / Zn): comprising the following steps,
[0071] (1) Poly(L-lactide-caprolactone) (PLCL) and zinc chloride (ZnCl2) were dissolved together in N,N-dimethylformamide to prepare a spinning solution with a PLCL mass fraction of 10% and a ZnCl2 mass fraction of 2%;
[0072] (2) Add the spinning solution into the electrospinning machine capacity tube for electrospinning. The spinning voltage is 18 kV, the receiving distance is 15 cm, the spinning solution propulsion speed is 1 mL / h, the receiving device is a steel tube with an outer diameter of 4 mm, the rotation speed is 300 rpm, and the spinning width is 15 cm.
[0073] (3) After the electrospinning is completed, the obtained spinning membrane is removed from the receiving device and placed in a vacuum drying oven for drying to obtain the artificial blood vessel substrate PLCL / Zn.
[0074] Example 9-Polyphenol-metal coating treatment on the surface of artificial blood vessels (PLCL / Zn-EGCG / Zn): comprising the following steps:
[0075] (1) The artificial blood vessel obtained in Example 8 was treated with PLCL / Zn plasma for 3 min;
[0076] (2) The artificial blood vessel treated with plasma was immersed in an aqueous solution containing epigallocatechin gallate (EGCG) / zinc chloride (ZnCl2) and shaken for 2 days, wherein the pH of the aqueous solution was 8.5, the concentration of EGCG was 0.30 mg / mL, and the concentration of ZnCl2 was 0.1 mg / mL, to obtain PLCL / Zn-EGCG / Zn.
[0077] Example 10-Introduction of polypeptide treatment on the surface of artificial blood vessels containing polyphenol-metal coating (PLCL / Zn-EGCG / Zn-REDV): comprising the following steps,
[0078] (1) The polyphenol-metal coated artificial blood vessel PLCL / Zn-EGCG / Zn obtained in Example 9 was immersed in an aqueous solution of REDV polypeptide containing a thiol functional group (SH-REDV, i.e. SH-arginine-glutamic acid-aspartic acid-valine, Hangzhou Zhuan Peptide Biotechnology Co., Ltd.) for 2 h, and the concentration of SH-REDV was 0.15 mg / mL;
[0079] (2) Drying the soaked artificial blood vessel in a nitrogen atmosphere to obtain an artificial blood vessel PLCL / Zn-EGCG / Zn-REDV with a polyphenol-metal-polypeptide coating.
[0080] Test example
[0081] 1. Actual picture of artificial blood vessel
[0082] Figure 1 This is a physical picture of the artificial blood vessel PCL / Cu prepared in Example 1;
[0083] Figure 2 This is a physical picture of the artificial blood vessel PCL / Cu-PDA / Cu-REDV prepared in Example 5.
[0084] Depend on Figure 1-Figure 2 It can be seen that the color of the artificial blood vessel deepens after being treated with the polyphenol-metal-peptide coating, indicating the successful preparation of the polyphenol-metal-peptide coating.
[0085] 2. Coating Adhesion
[0086] The tape test was used to compare the effect of whether the substrate was doped with metal ions on the adhesion of the coating.
[0087] Figure 3 These are the coating removal rate results of the tape test for the artificial blood vessel PCL / Cu-PDA / Cu-2 prepared in Example 3 and the artificial blood vessel PCL-PDA / Cu prepared in Example 4.
[0088] Depend on Figure 3 It can be seen that the introduction of metal ions that can interact with polyphenols into the porous polymer matrix can effectively improve the coating adhesion and reduce the removal rate of the coating in the tape test.
[0089] 3. NO release rate
[0090] The NO release rate was measured using the Griess reagent method.
[0091] Figure 4 This is a graph showing the results of the rate of release of nitric oxide from nitric oxide donors catalyzed by the artificial blood vessels PCL prepared in Example 2, and the artificial blood vessels PCL / Cu-PDA / Cu-1, PCL / Cu-PDA / Cu-2, PCL / Cu-PDA / Cu-3, and PCL / Cu-PDA / Cu-4 prepared in Example 3.
[0092] Depend on Figure 4 It can be seen that adjusting the copper ion content in the solution can effectively adjust the rate of catalytic release of nitric oxide by the material.
[0093] Figure 6 The graph shows the results of the rate of catalyzing the release of nitric oxide from nitric oxide donors after the artificial blood vessels PCL / Cu-PDA / Cu-2 prepared in Example 3 and the artificial blood vessels PCL-PDA / Cu prepared in Example 4 were immersed in PBS for different time periods.
[0094] 3. Water contact angle of materials after immersion for different time periods
[0095] Figure 5 The water contact angles of the artificial blood vessel PCL / Cu-PDA / Cu-2 prepared in Example 3 and the artificial blood vessel PCL-PDA / Cu prepared in Example 4 after being immersed in PBS for different time periods.
[0096] Depend on Figure 5 It can be seen that the introduction of metal ions that can interact with polyphenols into the porous polymer matrix can effectively improve the coating stability.
[0097] Depend on Figure 5 and Figure 6 It can be seen that by introducing metal ions that interact with polyphenols into the porous polymer matrix, the stability of the coating can be significantly improved. This enhanced stability enables the material to more effectively resist blood flushing after implantation in the body, maintain excellent hydrophilicity, and continuously and stably catalyze the release of NO, maintaining it within an appropriate physiological concentration range, thereby exerting good biological functions.
[0098] 4. SEM images of platelet adhesion
[0099] Figure 7 This is a scanning electron microscopic image of platelet adhesion of the artificial blood vessel PCL prepared in Example 2;
[0100] Figure 8 This is a scanning electron micrograph of platelet adhesion to the artificial blood vessel PCL / Cu-PDA / Cu-REDV containing a polyphenol-metal-polypeptide coating prepared in Example 5.
[0101] Depend on Figure 7-8 It can be seen that the polyphenol-metal-peptide coating can effectively improve the anti-platelet properties of artificial blood vessels.
[0102] 5. Endothelial cell adhesion
[0103] Human umbilical vein endothelial cells (ECs, obtained from West China Hospital of Sichuan University) were cultured at 37°C and 5% CO2. The culture medium used was Dulbecco's modified DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. ECs were cultured at 3 × 10 4 The density of cells / mL was directly inoculated on the sample surface, and after incubation for 1 and 3 days, the cell activity and proliferation were evaluated using the CCK-8 method.
[0104] Fig. 9These are the endothelial cell adhesion results of the artificial blood vessel PCL prepared in Example 2, the polyphenol-metal coated artificial blood vessel PCL / Cu-PDA / Cu-2 prepared in Example 3, and the polyphenol-metal-polypeptide coated artificial blood vessel PCL / Cu-PDA / Cu-REDV in Example 5.
[0105] Depend on Fig. 9 It can be seen that the polyphenol-metal coating can effectively improve the endothelial-promoting function of artificial blood vessels; and further introduction of REDV polypeptide can further improve the endothelial-promoting performance.
[0106] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. An anticoagulant and endothelial-promoting bionic artificial blood vessel, characterized in that: include: A porous polymer substrate and a coating bonded to the porous polymer substrate; the porous polymer substrate is doped with metal ions I; The metal ion I includes at least one of copper ion, iron ion, zinc ion, nickel ion, cobalt ion and manganese ion; The coating is a polyphenol-metal-polypeptide copolymer; the metal is a metal ion II that can catalyze the release of nitric oxide from an endogenous nitric oxide donor, and the metal ion II includes at least one of copper ions, iron ions, zinc ions, nickel ions, cobalt ions, and manganese ions; the polypeptide has at least one group bonded to the polyphenol-metal and at least one functional polypeptide sequence.
2. The anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 1, characterized in that: The raw material of the porous polymer substrate includes at least one of polylactic acid, polycaprolactone, polyglycolic acid, polycarbonate, polyurethane, polydioxanone, polyamide, polyether polyol and polyethylene terephthalate.
3. The anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 1, characterized in that: The forming method of the porous polymer substrate includes at least one of electrospinning, electrostatic direct writing, template method, freeze drying, 3D printing, solution spinning, melt spinning, foaming, weaving, and melt blowing.
4. The anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 1, characterized in that: The polyphenol-metal-polypeptide copolymer includes the following features (1-1): (1-1) The polyphenols include at least one of dopamine, gallic acid and its derivatives, tannic acid, pyrogallic acid, epicatechin, epigallocatechin, levodopa and dextrodopa.
5. The anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 4, characterized in that: Gallic acid and its derivatives include at least one of epicatechin gallate and epigallocatechin gallate.
6. The anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 1, characterized in that: The polypeptide comprises at least one of features (1-3-1) to (1-3-2): (1-3-1) The group includes at least one of carboxyl, hydroxyl, amino, hydrazide, mercapto, and isocyanate; (1-3-2) The functional polypeptide sequence includes at least one polypeptide sequence having the functions of anticoagulation, endothelial promotion, anti-inflammatory, antiplatelet, and inhibition of smooth muscle proliferation.
7. The anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 6, characterized in that: Feature (1-3-1): The group includes at least one of a thiol group, an amino group, and a hydrazide group.
8. The anticoagulant and endothelial-promoting bionic artificial blood vessel according to any one of claims 1 to 7, characterized in that: The porous polymer substrate is doped with metal ions I, comprising the characteristics (2-1): (2-1) The mass ratio of metal ion I to porous polymer substrate is 1:30~60.
9. The method for preparing an anticoagulant and endothelial-promoting bionic artificial blood vessel according to any one of claims 1 to 8, characterized in that: The steps include: S1 The porous polymer substrate is subjected to a hydrophilic treatment to obtain a first treated body; S2 placing the first treated body in a treatment solution containing polyphenol-metal ions to obtain a second treated body; S3 placing the second treated body in a treatment solution containing the polypeptide to obtain an anti-coagulation and endothelial-promoting bionic artificial blood vessel.
10. The method for preparing the anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 9, characterized in that: The hydrophilization treatment includes at least one of plasma treatment, cleaning treatment, and irradiation treatment.
11. The method for preparing the anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 10, characterized in that: The cleaning treatment includes at least one of acid solution treatment, alkali solution treatment, and sodium naphthalene treatment.
12. The method for preparing the anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 11, characterized in that: Acid treatment includes chromium pickling solution treatment.
13. The method for preparing the anticoagulant and endothelial-promoting bionic artificial blood vessel according to claim 9, characterized in that: In S2, the mass concentration of the treatment solution containing polyphenol-metal ions is 1-30%; and / or, in S3, the mass concentration of the treatment solution containing polypeptides is 0.5-50%.
